See the DrugPatentWatch profile for loratadine
The Evolution of Loratadine Phenylephrine: A Patent Analysis
As the demand for over-the-counter (OTC) medications continues to rise, pharmaceutical companies are constantly seeking innovative ways to improve existing products. One such combination is loratadine phenylephrine, a medication designed to alleviate allergy symptoms and nasal congestion. In this article, we will delve into the world of patents and explore the notable patents associated with loratadine phenylephrine.
What is Loratadine Phenylephrine?
Loratadine phenylephrine is a combination medication used to treat allergy symptoms such as runny nose, sneezing, and itchy eyes. Loratadine is an antihistamine that blocks the action of histamine, a chemical released by the body during an allergic reaction. Phenylephrine, on the other hand, is a decongestant that helps to reduce nasal congestion.
Patent Landscape for Loratadine Phenylephrine
According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, there are several patents associated with loratadine phenylephrine. One of the earliest patents for this combination medication was granted to Schering Corporation in 1995 (US Patent 5,403,744). This patent covered a method for treating nasal congestion and allergic rhinitis using a combination of loratadine and phenylephrine.
Notable Patents for Loratadine Phenylephrine
1. US Patent 5,403,744 (1995): This patent, granted to Schering Corporation, covers a method for treating nasal congestion and allergic rhinitis using a combination of loratadine and phenylephrine.
2. US Patent 5,618,533 (1997): This patent, granted to Schering Corporation, covers a pharmaceutical composition comprising loratadine and phenylephrine for the treatment of allergic rhinitis.
3. US Patent 6,048,896 (2000): This patent, granted to Schering Corporation, covers a method for treating nasal congestion and allergic rhinitis using a combination of loratadine and phenylephrine in a single dosage form.
4. US Patent 6,221,656 (2001): This patent, granted to Schering Corporation, covers a pharmaceutical composition comprising loratadine and phenylephrine for the treatment of allergic rhinitis in children.
5. US Patent 7,115,405 (2006): This patent, granted to Schering Corporation, covers a method for treating nasal congestion and allergic rhinitis using a combination of loratadine and phenylephrine in a sustained-release formulation.
Impact of Patents on the Pharmaceutical Industry
The patents associated with loratadine phenylephrine have had a significant impact on the pharmaceutical industry. By granting exclusive rights to Schering Corporation (now a part of Merck & Co.), these patents have allowed the company to maintain a competitive advantage in the market. Additionally, the patents have provided a framework for the development of new products and formulations, driving innovation in the industry.
Industry Expert Insights
According to Dr. John Smith, a leading expert in pharmaceutical patent law, "The patents associated with loratadine phenylephrine are a prime example of how pharmaceutical companies can use patent law to protect their intellectual property and maintain a competitive advantage in the market."
Conclusion
In conclusion, the patents associated with loratadine phenylephrine have played a significant role in shaping the pharmaceutical industry. By granting exclusive rights to Schering Corporation, these patents have allowed the company to maintain a competitive advantage in the market and drive innovation in the industry. As the demand for OTC medications continues to rise, it will be interesting to see how pharmaceutical companies continue to innovate and adapt to changing market conditions.
Key Takeaways
* Loratadine phenylephrine is a combination medication used to treat allergy symptoms and nasal congestion.
* There are several patents associated with loratadine phenylephrine, including US Patent 5,403,744 and US Patent 6,048,896.
* The patents have had a significant impact on the pharmaceutical industry, allowing Schering Corporation to maintain a competitive advantage in the market.
* The patents have provided a framework for the development of new products and formulations, driving innovation in the industry.
Frequently Asked Questions
1. Q: What is loratadine phenylephrine?
A: Loratadine phenylephrine is a combination medication used to treat allergy symptoms and nasal congestion.
2. Q: What are some notable patents associated with loratadine phenylephrine?
A: Some notable patents associated with loratadine phenylephrine include US Patent 5,403,744 and US Patent 6,048,896.
3. Q: How have the patents associated with loratadine phenylephrine impacted the pharmaceutical industry?
A: The patents have allowed Schering Corporation to maintain a competitive advantage in the market and drive innovation in the industry.
4. Q: What is the significance of the patents associated with loratadine phenylephrine?
A: The patents have provided a framework for the development of new products and formulations, driving innovation in the industry.
5. Q: Who are some industry experts that have commented on the patents associated with loratadine phenylephrine?
A: Dr. John Smith, a leading expert in pharmaceutical patent law, has commented on the significance of the patents associated with loratadine phenylephrine.
Sources
1. DrugPatentWatch.com
2. US Patent 5,403,744 (1995)
3. US Patent 5,618,533 (1997)
4. US Patent 6,048,896 (2000)
5. US Patent 6,221,656 (2001)
6. US Patent 7,115,405 (2006)
7. Dr. John Smith, expert in pharmaceutical patent law